Literature DB >> 2384149

3,4-Dichloroisocoumarin, a serine protease inhibitor, inactivates glycogen phosphorylase b.

N M Rusbridge1, R J Beynon.   

Abstract

3,4-Dichloroisocoumarin (3,4-DCI) is a highly reactive, mechanism-based inhibitor of serine proteases. We show here that glycogen phosphorylase b is also inactivated by this inhibitor, in a mechanism that parallels the inactivation of serine proteases, but involving multiple sites of covalent modification. Such a process may compromise studies in which 3,4-DCI is used to arrest proteolysis of a second native protein which may itself be modified.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2384149     DOI: 10.1016/0014-5793(90)80991-q

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  3 in total

1.  Inducible phosphorylation of I kappa B alpha is not sufficient for its dissociation from NF-kappa B and is inhibited by protease inhibitors.

Authors:  T S Finco; A A Beg; A S Baldwin
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

2.  Preprocalcitonin signal peptide generates a cytotoxic T lymphocyte-defined tumor epitope processed by a proteasome-independent pathway.

Authors:  Faten El Hage; Vincent Stroobant; Isabelle Vergnon; Jean-François Baurain; Hamid Echchakir; Vladimir Lazar; Salem Chouaib; Pierre G Coulie; Fathia Mami-Chouaib
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-14       Impact factor: 11.205

3.  Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours.

Authors:  Aurélie Durgeau; Yasemin Virk; Gwendoline Gros; Elodie Voilin; Stéphanie Corgnac; Fayçal Djenidi; Jérôme Salmon; Julien Adam; Vincent de Montpréville; Pierre Validire; Soldano Ferrone; Salem Chouaib; Alexander Eggermont; Jean-Charles Soria; François Lemonnier; Eric Tartour; Nathalie Chaput; Benjamin Besse; Fathia Mami-Chouaib
Journal:  Nat Commun       Date:  2018-11-30       Impact factor: 14.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.